Cure Innovation Index U.S.-China Biotech Competitiveness Report (IMAGE)
Caption
This is the first page of Cure's 14-page U.S.-China Biotech Competitiveness Report. Download the complete Cure Innovation Index U.S.-China Biotech Competitiveness Scorecard report for the rich data visuals of findings and methodology.
The United States leads China in the quality, commercial depth, and frontier intensity of its biomedical science. China leads in the speed, scale, and cost of converting science into medicines. Five Cure Innovation Index analyses map both sides of this divide and where the race will be decided:
- a survey of senior U.S. industry and academic leaders fielded in June 2026
- three bibliometric studies of the top 10 biomedical research institutions in each country
- a clinical trial infrastructure and commercial embeddedness analysis across U.S. and Chinese institutions.
Credit
Cure Innovation Index
Usage Restrictions
Credit must be given to the creator.
License
CC BY